Ziprasidone in the treatment of delayed carbon monoxide encephalopathy | Canada Hyperbarics Skip to main content
Case Report Prog Neuropsychopharmacol Biol Psychiatry 2006

Ziprasidone in the treatment of delayed carbon monoxide encephalopathy

Hu M, Shiah I, Yeh C, Chen H, Chen C — Prog Neuropsychopharmacol Biol Psychiatry, 2006

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

This case report describes a 52-year-old woman who developed severe brain and mental symptoms one week after acute carbon monoxide poisoning, and how her condition improved after treatment with the medication ziprasidone.

What They Found

The patient initially received hyperbaric oxygen therapy for acute carbon monoxide poisoning and later daily hyperbaric oxygen therapy during hospitalization, along with several other medications. Despite these treatments, she continued to suffer from severe neuropsychiatric symptoms, including movement disorders, cognitive decline, and disorientation. After 10 days of treatment with ziprasidone (80 mg/day), her mental condition, cognitive function, and ability to perform daily activities showed substantial improvement.

What This Means for Canadian Patients

Delayed carbon monoxide encephalopathy can lead to serious and lasting brain and mental health issues for Canadian patients. This case suggests that ziprasidone could be a potential treatment option for those who continue to experience severe neuropsychiatric symptoms after carbon monoxide poisoning, even after receiving initial hyperbaric oxygen therapy and other medications. It underscores the need for diverse treatment approaches for complex post-poisoning complications.

Canadian Relevance

This study was not conducted by Canadian authors or in Canada. However, carbon monoxide poisoning is a Health Canada-recognized indication for hyperbaric oxygen therapy, and this study addresses a serious complication of this condition.

Study Limitations

As a single case report, these findings cannot be broadly applied to all patients with delayed carbon monoxide encephalopathy.

Was this summary helpful?

Study Details

Study Type Case Report
Category Neurological
Source Pubmed
PubMed ID 16581170
Year Published 2006
Journal Prog Neuropsychopharmacol Biol Psychiatry
MeSH Terms Antipsychotic Agents; Brain Diseases; Carbon Monoxide Poisoning; Female; Humans; Middle Aged; Piperazines; Thiazoles

Cite This Study

Share
Discuss with a qualified healthcare professional. Then: Review Coverage Guide View Recognised Conditions

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.